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Antenatal Glucocorticoid Treatment: Are We Doing
Harm to Term Babies?
Rebecca M. Reynolds and Jonathan R. Seckl
Endocrinology Unit, University/British Heart Foundation Centre for Cardiovascular Science, University of
Edinburgh, Queen’s Medical Research Institute, Edinburgh EH16 4TJ, United Kingdom
Antenatal glucocorticoids are given to 7–10% ofwomen in Europe and North America at threat of
preterm labor. It is undisputed that this therapy signifi-
cantly reduces neonatalmorbidity andmortality in infants
born before 34 wk gestation (1, 2). Based on outcomes
frommultiple clinical trials, current obstetric practice is to
administer either a single 2-d course of betamethasone or
dexamethasone (i.e. two 12-mg doses of betamethasone
im at 24-h intervals or four 6-mg doses of dexamethasone
im at 12-h intervals) to women in preterm labor between
24 and 34 wk gestation (3). The use of repeat courses of
antenatal glucocorticoids is more controversial, although
some evidence suggests that a repeat course, if the mother
does not deliver but remains at risk of preterm labor, may
yield neonatal benefit (2). However, because early clinical
diagnosis of preterm labor is difficult and there are no
reliable laboratory tests, there are a substantial number of
women who receive antenatal glucocorticoid treatment
yet subsequently deliver babies at full term, i.e. after 37wk
gestation. Little is known about the potential risks or ben-
efits of synthetic glucocorticoid exposure to these infants.
It is nowwell recognized that exposure to an adverse in
utero environment during development has long-term ef-
fects on physiology and later risk of adult disease (4).
Overexposure of the developing fetus to excess glucocor-
ticoids is a key mechanism thought to underlie such “de-
velopmental programming” (4). Numerous preclinical
studies have shown that administrationof dexamethasone
to pregnant mothers leads to long-term changes in the
offspring, notably permanently altering cardiometabolic
and neuropsychiatric functions as well as hypothalamic-
pituitary-adrenal (HPA) axis activity (4). The latter may
contribute to some of the broader pathogenesis associated
with experimental programming.
Both betamethasone and dexamethasone have high af-
finity for glucocorticoid receptors but are poor substrates
for the placental enzyme 11- hydroxysteroid dehydro-
genase type 2, which normally acts as a partial barrier,
protecting the fetus from glucocorticoids by breaking
down endogenous cortisol into inactive cortisone (4).
These synthetic glucocorticoids readily cross the placenta,
potentially exposing the fetus to excess glucocorticoids. In
animal models, the developing HPA axis appears partic-
ularly vulnerable to excess glucocorticoids (4), yet the ev-
idence for detrimental effects of antenatal glucocorticoids
on human HPA axis activity has been less clear-cut. This
is partly because most studies have included preterm in-
fants, who often have coexisting medical complications
and are exposed to stressors and painful procedures while
in the neonatal intensive care unit, factors that can per se
alter HPA axis function (5). Likewise, the type, dose, and
timing of administration of glucocorticoid therapy often
differ between studies, complicating interpretation. Fur-
thermore, studies have included limited assessments of the
offspring HPA axis, often with a single measurement of
cortisol levels. Given these caveats, the limited existing
data, which include pretermbabies inwhom theHPA axis
may be immature, suggest that among infants exposed to
antenatal glucocorticoids, baseline cortisol levels are sup-
pressed during the first postnatal week, and cortisol re-
sponses to the painful stress of the heel-stick procedure are
suppressed for up to 8 wk (6), suggesting some persistent
suppressive effects onHPA axis regulation, but hardly the
programming of increased (or reduced) HPA activity seen
throughout the lifespan in animal models.
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Abbreviation: HPA, Hypothalamic-pituitary-adrenal.
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In the article by Alexander et al. (7) in this issue of the
JCEM, the authors report on the first study to examine the
impact of antenatal synthetic glucocorticoid exposure on
endocrine stress reactivity in term-born children aged
6–10 yr. Maternal stress has itself been implicated as a
programming factor (4), and hospitalized women receiv-
ing antenatal glucocorticoids are likely to bemoreworried
and “stressed.” Alexander et al. (7) therefore introduced
an additional control group of stressed mothers who had
been admitted to hospital with pregnancy complications
but had not received antenatal glucocorticoids. This care-
ful studydesigngoes someway todisentangle thepotential
confounding effect of maternal stress from the direct ef-
fects of antenatal glucocorticoid exposure.
The children exposed to antenatal glucocorticoidswere
smaller at birth and were born slightly earlier than the
control groups; these variableswere includedas covariates
in the statistical analysis. The main finding was that chil-
dren exposed to antenatal glucocorticoid treatment had
significantly increased cortisol reactivity to a standardized
laboratory stressor, the Trier Social Stress Test for Chil-
dren (TSST-C), compared with both control groups. Al-
though these data are the most comprehensive to date,
they are still cross-sectional and observational. Prospec-
tive data with longitudinal follow-up are necessary to
confirm the findings and overcome any possible bias in
recruitment/retention. Nevertheless, these findings are
consistentwitha recent study showingamorepronounced
cortisol response to the heel-stick procedure among term
infants exposed to betamethasone in utero, compared
with an unexposed control group (8), and suggest long-
lasting effects of antenatal glucocorticoid exposure on
HPA axis reactivity. Alexander et al. (7) also found that
cortisol reactivity to the TSST-Cwasmore pronounced in
girls than boys, a finding that is consistent with the sex-
ually dimorphic responses in animal studieswhere females
are generally more susceptible to programming of HPA
axis stress responsivity (9). Increased HPA axis activity
during themorning diurnal peak has also been reported in
children of mothers who voluntarily consumed higher
quantities of the 11- hydroxysteroid dehydrogenase type
2 inhibitor licorice in pregnancy (10).
What are the implications of increased HPA axis stress
reactivity in these children? From an evolutionary per-
spective, such an adaptation to an intrauterine insult is
thought to be beneficial in the short-term and linked to
increased chanceof offspring survival in apredicted stress-
ful environment, and hence increased chances of survival
to reproductive age (11). However, such adaptations may
be detrimental in the longer term. For example, in adult
men and women, activation of the HPA axis has been
linked to increased risk of cardiovascular risk factors com-
prising the metabolic syndrome including higher glucose,
blood pressure, and triglycerides (12), as well as ischemic
heart disease, cognitive decline, and depression (12) in
later life. Indeed, in preterm infants, antenatal glucocor-
ticoid exposure has been associated with an increase in
behavioral disorders at age 3 yr (13), higher systolic and
diastolic blood pressures in adolescence (14), and in-
creased insulin resistance, a precursor of type 2 diabetes,
at age 30 yr (15). Whether or not the HPA axis hyperac-
tivity observed by Alexander et al. (7) contributes to such
effects remains to be determined.
There is no doubt that antenatal glucocorticoid treat-
ment for women in preterm labor has benefits for preterm
babies, and this justifies the small risk of long-term side
effects. Yet with this emerging evidence of potential harm
for term infants and no evidence of benefits, it is crucial
that we develop ways to accurately identify those women
at the greatest risk of preterm labor. Approaches might
employ biological markers such as fetal fibronectin as a
test of exclusion of preterm labor (16), or the research tool
of measurement of cervical length by transvaginal ultra-
sonography (17). In addition, in 2011, the U.S. Food and
Drug Administration approved the use of progesterone
supplementation (hydroxyprogesterone caproate) during
pregnancy to reduce the risk of recurrent preterm birth in
women with a history of at least one prior spontaneous
preterm delivery (18). Such strategies may avoid unnec-
essary glucocorticoid treatment of those women who go
on to deliver beyond 37 wk gestation. However, recent
Royal College of Obstetrics and Gynaecology guidelines
in the United Kingdom recommend routine administra-
tion of antenatal glucocorticoids for all women undergo-
ing elective cesarean section at less than 39 wk gestation
(19). Although endogenous glucocorticoids rise dramati-
cally in pregnancy, peaking in the third trimester at three
times nonpregnant levels (20), the long-term effects of ex-
ogenous glucocorticoid exposure in late pregnancy for
these children are unknown. A further approach is to con-
sider minimizing the doses of glucocorticoids used. Al-
though Alexander et al. (7) observed no differences in
childhoodcortisol stress responses according to the typeof
glucocorticoid used, data in a nonhuman primate model
suggest dose-associated programming of cardiometabolic
parametersbydexamethasone (21), implying that the low-
est dose of glucocorticoid possible should be used to min-
imize long-term adverse effects. This principle is well-es-
tablished in adult glucocorticoid therapy and might
beneficially be incorporated into obstetric thinking as
well.
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